Serilink Biotechnology Company Limited
- Biotech or pharma, therapeutic R&D
- Diagnostics
- Medical device or technology
- Synthesis, analytic, diagnostic services
- Other R&D services
Serilink specializes in the synthesis and modifications of peptide/protein drugs, and bioconjugations between small molecules and bio-macromolecules, by utilizing our in-house-developed patented novel technology (OPA LinkTech). We are focusing on building a high-tech biologic therapeutics research platform for developing ADCs (antibody-drug conjugates), ARCs (antibody-radionuclide conjugates) and PDCs (peptide-drug conjugates), collectively referred as XDCs.
Serilink is providing plug-and-play kits for easy preparation of small scale bioconjugates. We also collaborate with partners to co-develop drugs, aiming at advancing them to the PCC or further to IND stage.
We develop structurally innovative and performance-enhanced conjugated drug candidate compounds, empowering pharmaceutical companies in need of transformation and innovation, and providing new drug molecules and platform development technologies.